45019-30-5

Basic information

• Product Name: 4-(butylamino)-4-oxobut-2-enoic acid
• CAS NO: 45019-30-5
• Molecular Formula: C₈H₁₃NO₃
• Molecular Weight: 171.1937
• Mol File: 45019-30-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 381.6°C at 760 mmHg
• Flash Point: 184.6°C
• Density: 1.106g/cm³
• Vapor Pressure: 7.03E-07mmHg at 25°C
• Refractive Index: 1.485
• CAS DataBase Reference: 4-(butylamino)-4-oxobut-2-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(butylamino)-4-oxobut-2-enoic acid(45019-30-5)
• EPA Substance Registry System: 4-(butylamino)-4-oxobut-2-enoic acid(45019-30-5)

Safety Data

• Hazardous Substances Data: 45019-30-5(Hazardous Substances Data)

Upstream product

• 108-31-6 maleic anhydride 
• 109-73-9 N-butylamine 

Downstream Products

• 80991-63-5 N-n-butylmaleisoimidium perchlorate 
• 92989-16-7 (Z)-Butyl methyl maleamate 
• 189129-27-9 (E)-Butyl methyl maleamate 
• 41187-40-0 1-butyl-3-(phenylamino)pyrrolidine-2,5-dione 
• 85038-14-8 1-butyl-3-(phenylamino)-1H-pyrrole-2,5-dione 
• 115355-58-3 1-Butyl-3-[1-dimethylamino-meth-(Z)-ylidene]-4-[(E)-phenylimino]-pyrrolidine-2,5-dione 
• 27396-39-0 maleic acid N-butylisoimide 
• 108-31-6 maleic anhydride 
• 109-73-9 N-butylamine 

Relevant articles and documents

-

-

Anti-leishmanial and cytotoxic activities of a series of maleimides: Synthesis, biological evaluation and structure-activity relationship

In the present study, 45 maleimides have been synthesized and evaluated for anti-leishmanial activities against L. donovani in vitro and cytotoxicity toward THP1 cells. All compounds exhibited obvious anti-leishmanial activities. Among the tested compounds, there were 10 maleimides with superior anti-leishmanial activities to standard drug amphotericin B, and 32 maleimides with superior anti-leishmanial activities to standard drug pentamidine, especially compounds 16 (IC50 50 50 > 10 μg/mL). The anti-leishmanial activities of 16 and 42 were 10 times better than that of amphotericin B. The structure and activity relationship (SAR) studies revealed that 3,4-non-substituted maleimides displayed the strongest anti-leishmanial activities compared to those for 3-methyl-maleimides and 3,4-dichloro-maleimides. 3,4-dichloro-maleimides were the least cytotoxic compared to 3-methyl-maleimides and 3,4-non-substituted maleimides. The results show that several of the reported compounds are promising leads for potential anti-leishmanial drug development.

Comparison of pH-sensitive degradability of maleic acid amide derivatives

We synthesized five maleic acid amide derivatives (maleic, citraconic, cis-aconitic, 2-(2′-carboxyethyl) maleic, 1-methyl-2-(2′- carboxyethyl) maleic acid amide), and compared their degradability for the future development of pH-sensitive biomaterials with tailored kinetics of the release of drugs, the change of charge density, and the degradation of scaffolds. The degradation kinetics was highly dependent upon the substituents on the cis-double bond. Among the maleic acid amide derivatives, 2-(2′-carboxyethyl) maleic acid amide with one carboxyethyl and one hydrogen substituent showed appropriate degradability at weakly acidic pH, and the additional carboxyl group can be used as a pH-sensitive linker.